References for Hepatitis C: Epidemiology and Review of Complementary/Alternative Medicine Treatments

[Guest guest]

Hepatitis C: Epidemiology and Review of

Complementary/Alternative Medicine Treatments

by Lyn , ND

References

1. World Health Organization. Hepatitis C: global

prevalence. Wkly Epidemiol Rec 1997;10:65-72.

2. Sherlock S. Clinical features of hepatitis. In:

Zuckerman AJ, HC, eds. Viral Hepatitis, 2nd ed.

London: Churchill Livingston; 1998:1-13.

3. Births and Deaths, Preliminary data for 1997. Natl

Vital Stat Rep 1998;47:1-8. NIH Consensus Development

Conference.

4. NIH Consensus Development Conference: Management of

Hepatitis C. April 27, 1998. National Institutes of

Health, Bethesda, land.

5. Di Bisceglie AM, Order SE, Klein JK, et al. The

role of chronic viral hepatitis in hepatocellular

carcinoma in the United States. Am J Gastoenterol

1991;86:335-338.

6. KL. Therapy of hepatitis C: an overview.

NIH Consensus Development Conference: Management of

Hepatitis C. April 1998. National Institutes of

Health, Bethesda, land.

7. Carithers RL. Therapy of hepatitis C: Interferon

Alfa-2B. NIH Consensus Development Conference:

Management of Hepatitis C. April 1998. National

Institutes of Health, Bethesda, land.

8. Nishiguchi S, Kuroki R, Nakatani S, et al.

Randomized trial of effects of interferon-alfa on

incidence of hepatocellular carcinoma in chronic

active hepatitis C with cirrhosis. Lancet

1995;346:1051-1055.

9. McHutchinson JG, Gordon SC, Schiff ER, et al.

Interferon alfa-2b alone or in combination with

ribavirin as initial treatment for chronic hepatitis

C. N Eng J Med 1998;339:1485-1492.

10. Sherman A. HCV on the threshold. Infect Med

1999;16:92-94.

11. Purcell R. The hepatitis C virus: overview. NIH

Consensus Development Conference: Management of

Hepatitis C. Hepatology 1997;26:11S-14S.

12. Mozzi F, Rebulla T, Locatelli E, et al. Antibody

to hepatitis C virus in Italian thalassemics evaluated

with second generation tests. Proceedings of the Third

International Symposium on Hepatitis C Virus.

Strasbourg, France 1991:90.

13. Locasciolli A, Gornati G, Tagger A, et al.

Hepatitis C virus infection and chronic liver disease

in children with leukemia in long term remission.

Blood 1991;88:53-54.

14. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ.

The risk of transfusion-transmitted viral infections.

N Engl J Med 1996;334:1685-1690.

15. Brown D, Manolakopoulos S, Dusheiko G. Diagnosis

of acute and chronic hepatitis C. In: Zuckerman AJ,

HC. eds. Viral Hepatitis, 2nd ed. London:

Churchill Livingston; 1998:319-338.

16. Dusheiko G, Schmilovitz-Weiss H, Brown D, et al.

Hepatitis C virus genotypes: an investigation of

type-specific differences in geographic origin of

disease. Hepatology 1994;19:13-18.

17. Yoshioka K, Kakumu S, Wakita T, et al. Detection

of hepatitis C virus by polymerase chain reaction and

response to interferon-alpha therapy: relationship to

genotypes of hepatitis C virus. Hepatology

1992;16:293-299.

18. McGarvey MJ, Houghton M, Weiner AJ. Structure and

molecular virology. In: Zuckerman AJ, HC. eds.

Viral Hepatitis, 2nd ed. London: Churchill Livingston;

1998:253-269.

19. Alter MJ. Epidemiology of hepatitis C. Hepatology

1997;26:62S-65S.

20. Akahane Y, Kojima M, Sugai Y. Hepatitis C viral

infection in spouses of patients with type C chronic

liver disease. Ann Intern Med 1994;120:748-752.

21. Reinus JF, Leikin EL, Later HJ, et al. Failure to

detect vertical transmission of hepatitis C virus. Ann

Int Med 1992;117:881-886.

22. Conry-Cantilena C, VanRaden MA, Gibble J, et al.

Routes of infection, viremia, and liver disease in

blood donors found to have hepatitis C virus

infection. N Engl J Med 1996;334:1691-1696.

23. Alter MJ. Epidemiology of hepatitis C in the west.

Semin Liver Dis 1995;15:5-14.

24. Allander T, Gruber A, Naghavi M, et al. Frequent

patient-to-patient transmission in a hematology ward.

Lancet 1995;345:603-607.

25. Esteban JI, Gomez J, Martell M, et al.

Transmission of hepatitis C virus by a cardiac

surgeon. N Engl J Med 1996;334:555-560.

26. Dienstag JL. Non-A, non-B hepatitis. I.

Recognition, epidemiology, and clinical features.

Gastroenterol 1983;85:439-462.

27. McGaughan GW, McGuiness PH, Bishop GA, et al.

Clinical assessment and incidence of hepatitis C RNA

in 50 consecutive RIBA-positive volunteer blood

donors. Med J Aust 1992;157:231-233.

28. Alter HJ, Purcell RH, Fienstone SM, et al. Non-A,

non-B hepatitis: a review and interim report of an

ongoing prospective study. In: Szmuners W, Alter HJ,

Maynard JE, eds. Viral Hepatitis: 1981 International

Symposium. Philadelphia, PA: lin Institute Press,

1982:359-369.

29. Kiyosawa K, Sodeyama T, Tanaka E, et al. Natural

history of hepatitis C. Intervirology 1994;37:101-107.

30. Hoofnagle J. Hepatitis C: the clinical spectrum of

disease. Hepatology 1997;26:15S-20S.

31. Okuda A. Natural history of chronic hepatitis C

and hepatocellular carcinoma. In Zuckerman AJ,

HC, eds. Viral Hepatitis, 2nd ed. London: Churchill

Livingstone; 1998:309-318.

32. Prieto P, Plasp V, Verdu C, et al. Does the

healthy hepatitis C virus carrier state really exist?

An analysis using polymerase chain reaction.

Hepatology 1995;22:413-417.

33. Mercan I, Sherlock S, McIntyre N, et al. Clinical,

biochemical and histological features in 102 patients

with chronic hepatitis C virus infection. Quart J Med

1993;86:119-125.

34. Agnello V, Chung RT, Kaplan LM. A role of

hepatitis C virus infection in type II

cryoglobulinemia. N Engl J Med 1992;327:1490-1495.

35. DeCastro M, J, Herrera JF, et al.

Hepatitis C virus antibodies and liver disease in

patients with porphyria cutanea tarda. Hepatology

1992;16:231. [Abstract]

36. Sulkowski MS. Hepatitis C virus and HIV

coinfection. CRIA Update 1998;8:15-18.

37. HG, Zhang LQ, P, et al. Hepatitis C

viral load increases with time after HIV infection.

Int Conf AIDS 1992;July:19-24; B195 (abstract # PoB

3629).

38. Darby SC, Ewart DW, Giagrande PLF, et al.

Mortality from liver cancer and liver disease in

hemophiliac men and boys in UK given blood products

contaminated with hepatitis C. Lancet

1997;350:1425-1431.

39. Nishioka K, Watanabe J, Furuta S, et al. A high

prevalence of antibody to the hepatitis C virus with

hepatocellular carcinoma in Japan. Cancer

1991;67:429-433.

40. Bruix J, Barrera JM, Calvet X, et al. Prevalence

of antibodies to hepatitis C virus in Spanish patients

with hepatocellular carcinoma and hepatic cirrhosis.

Lancet 1989;28:1004-1006.

41. Bisceglie AM. Hepatitis C and hepatocellular

carcinoma. NIH Consensus Development Conference:

Management of Hepatitis C. Program and Abstracts.

Office of the Director, National Institutes of Health.

March 24, 1997. National Institutes of Health,

Bethesda, land.

42. Zoli M, Magalotti D, Bianchi G, et al. Efficacy of

a surveillance program for early detection of

hepatocellular carcinoma. Cancer 1996;78:977-985.

43. Levine R. Treating histologically mild chronic

hepatitis C: monotherapy, combination therapy, or

tincture of time? Ann Intern Med 1998;129:323-326.

44. Haber MM, West AB, Haber AD, et al. Relationship

of aminotransferase to liver histological status in

chronic hepatitis C. AM J Gastroenterology

1995;90:1250-1257.

45. Bedosa P, Poynard T. An algorithim for the grading

of activity in chronic hepatitis C. The METAVIR

ative Study Group. Hepatology 1996;24:289-293.

46. Poynard T, Bedosa P, Opolon P. Natural history of

lower fibrosis progression in patients with chronic

hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and

DOSVIRC groups. Lancet 1997;349:825-832.

47. Bader TF. Clinical features of hepatitis C. In:

Bader TF, ed. Viral Hepatitis, Practical Evaluation

and Treatment 1st ed. Seattle, WA: Hogrefe & Huber;

1997.

48. Scheuer PJ, Ashrefzadeh P, Sherlock S, et al. The

pathology of hepatitis C. Hepatology 1992;15:567-571.

49. Bach N, Thung S, Schnafer F. The histological

features of chronic hepatitis C and autoimmune chronic

hepatitis: a comparative analysis. Hepatology

1992;15:572-577.

50. -Peralta RP, Lau JYN. Pathogenic

mechanisms for hepatocellular damage in chronic

hepatitis C virus infection. Semin Gastro

1995;6:28-34.

51. Lim HL, DR, Fang JWS. The tumor necrosis

factor-alpha system in chronic hepatitis C. Hepatology

1994;20:251A.

52. O'Garra A. Interleukins and the immune system 1.

Lancet 1989;1:943-946.

53. Clerici M, Shearer GM. A TH1 to TH2 switch is a

critical step in the etiology of HIV infection.

Immunol Today 1993;14:107-111.

54. Personal communication; July 1999. Bouic,

PhD, Dept. of Medical Microbiology, Medical Faculty,

University of Stellenbosch, Tygerberg 7505, South

Africa.

55. Lirussi F, B, Pelizzari L, et al. Natural

killer cells in patients with chronic hepatitis C

(CHC). Gut 1998;42:A32.

56. Chemello L, Cavaletto L, Bernardinello E, et al.

The effect of interferon alfa and ribavirin

combination therapy in naïve patients with chronic

hepatitis C. J Hepatol 1995;23:S8-S12.

57. Reichard O, Yun Z-B, Sonnerborg A, et al.

Hepatitis C viral RNA titers in serum prior to, during

and after oral treatment with ribavirin for chronic

hepatitis C. J Med Virol 1993;41:99-102.

58. Di Bisceglie AM, Bacon BR, Kleiner DE, et al.

Increase in hepatic iron stores following prolonged

therapy with ribavirin in patients with chronic

hepatitis C. J Hepatol 1994;21:1109-1112.

59. Dusheiko G, Main J, HC, et al. Ribavirin

treatment for patients with chronic hepatitis C:

results of a placebo controlled study. J Hepatol

1996;25:591-598.

60. Gane EJ, Su-Kong L, Riordan SM, et al. A

randomized study comparing ribavirin and interferon

alfa monotherapy for hepatitis C recurrence after

liver transplantation. Hepatology 1998;27:1403-1407.

61. Ning Q, Brown D, Parodo J. Ribavirin inhibits

procoagulant activity and viral induced macrophage

production of TNF and IL1, while preserving TH1

cytokine production and inhibiting TH2 cytokine

response. Hepatology 1996;24:355A.

62. Salen G, Ahrens EH, Grundy AM. Metabolism of

beta-sitosterol in man. J Clin Invest 1970;49:952-967.

63. Bouic PJD, Etsebeth RW, Liebenberg CF.

Beta-sitosterol and beta-sitosterol glucoside

stimulate human peripheral blood lymphocyte

proliferation: implications for their use as an

immunomodulatory vitamin combination. Int J

Immunopharmac 1996;18:693-700.

64. Weihrach JL, Gardner JM. Sterol content of foods

of plant origin. J Amer Diet Assoc 1978;73:39-47.

65. Yamamoto M, Matsui T, Sugiyama K, et al.

Anti-inflammatory active constituents of Aloe

arborescens . Agric Biol Chem 1991;55:1627-1629.

66. Ivorra MD, D'Ocon MP, Paya M, et al.

Anti-hyperglycemic and insulin releasing effects of

beta-sitosterol 3-B-D-glucoside and its aglycone

beta-sitosterol. Arch Int Pharmacodyn Ther

1988;296:224-231.

67. Carbin BE, Larsson B, ke O. Treatment of

benign prostatic hyperplasia with phytosterols. B J

Urol 1990;66:629-641.

68. Pegel KH. The importance of sitosterol and

sitosterolin in human and animal nutrition. S Afr J

Sci 1997;93:263-268.

69. Bouic PJD. Sterols/sterolins, nontoxic

immunomodulators and their role in the control of

rheumatoid arthritis. Newsletter of the Arthritis

Trust of America; Summer 1998.

70. Bouic PJD. Immunomodulation in HIV/AIDS: The

Tygerberg/Stellenbosch University Experience. AIDS

Bulletin 1997;6:18-20.

71. Personal communication; July 1999. Bouic,

PhD, Dept. of Medical Microbiology, Medical Faculty,

University of Stellenbosch, Tygerberg 7505, South

Africa.

72. Pinto HC, Baptista A, Camilo ME, et al.

Nonalcoholic steatohepatitis. Clinicopathological

comparison with alcoholic hepatitis in ambulatory and

hospitalized patients. Dig Dis Sci 1996;41:172-179.

73. Letteron P, Fromenty B, Terris B, et al. Acute and

chronic hepatitic steatosis lead to in vivo lipid

peroxidation in mice. J Hepatol 1996;24:200-208.

74. MacSween RNM. Pathology of viral hepatitis and its

sequelae. Clin Gastroenterol 1980;9:23-45.

75. Day CP, OFW. Hepatic steatosis: innocent

bystander or guilty party? Hepatology

1998;27:1463-1465.

76. Reeves HL, Burt AD, Wood S, et al. Hepatic

stellate cell activation occurs in the absence of

hepatitis in alcoholic liver disease and correlates

with the severity of steatosis. J Hepatol

1996;25:677-683.

77. Wenzel G, Kulinski B, Ruhlman C. Alcohol-induced

toxic hepatitis ­ a free radical associated disease.

Lowering fatality by adjuvant antioxidant therapy. Z

Gesamte Inn Med 1993;48:490-496.

78. Reizis AR, Malinovskaia VV, Shekhade S, et al.

Effectiveness of using recombinant interferon alfa2

(reaferon) combined with antioxidants in children with

acute hepatitis B. Pediatriia 1992;1:60-64. [Article

in Russian]

79. Beloqui O, Prieto J, Suarez M, et al. N-acetyl

cysteine enhances the response to interferon-alpha in

chronic hepatitis C: a pilot study. J Interferon Res

1993;13:279-282.

80. Hoglum K, Ventkataramani A, Lyche K, et al. A

pilot study of the effects of d-alpha tocopherol on

hepatic stellate cell activation in chronic hepatitis

C. Gastroenterology 1997;113:1069-1073.

81. Fujisawa K, Tandon BN. Therapeutic approach to the

chronic active liver disease: Summary of a satellite

symposium. In: Nishioka K, Suzuki H, Mishiro S, et al.

eds. Viral Hepatitis and Liver disease. Tokyo:

Springer; 1994:662-665.

82. Hattori M. Metabolism of glycyrrhizin by human

intestinal flora II. Isolation and characterization of

human intestinal bacteria capable of metabolizing

glycyrrhizin and related compounds. Chem Pharm Bull

1985;33:210-217.

83. Nose M, Ito M, Kamimura K, et al. A comparison of

the anti-hepatotoxic activity between glycyrrhizin and

glycyrrhetinic acid. Planta Med 1994;60:136-139.

84. Abe N, Ebina T, Ishida N. Interferon induction by

glycyrrhizin and glycyrrhetinic acid in mice.

Microbiol Immunol 1982;26:535-539.

85. Pompei R, Flore O, Marccialis MA, et al.

Glycyrrhizic acid inhibits virus growth and

inactivates virus particles. Nature 1979;281:689-690.

86. Crance JM, Biziagos E, Passagot J, et al.

Inhibition of hepatitis A virus replication in vitro

by antiviral compounds. J Med Virol 1990;31:155-160.

87. Crance JM, Leveque F, Biziagos E, et al. Studies

on the mechanism of action of glycyrrhizin against

hepatitis A virus replication. Antiviral Res

1994;23:63-76.

88. Nagai T, Egashira T, Yamanaka Y, et al.

Attenuation of dysfunction in the ischemia-reperfusion

liver by glycyrrhizin. Arch Environ Contam Toxicol

1991:20;432-436.

89. Kimura M, Watanabe H, Abo T. Selective activation

of extrathymic T cells in the liver by glycyrrhizin.

Biotherapy 1992;5:167-176.

90. Suzuki H, Ohta Y, Takino T, et al. The therapeutic

effects of Stronger Neo Minophagen C for chronic

hepatitis. Igaku no Ayumi 1977;102:562-568.

91. Hino K, Miyakawa H, Kondo T, et al. Effects of

glycyrrhizin therapy on liver histology in chronic

aggressive hepatitis. In: Shikata T, Purcell RH,

Uchida T, eds. Viral Hepatitis C, D, and E. Amsterdam:

Excerpta Medica; 1987:295-303.

92. Yasuda K, Hino K, Fujioka S, et al. Effects of a

high dose therapy with Stronger Neo Minophagen C

(SNMC) on hepatic histography in non-A, non-B chronic

active hepatitis. In: Shikata T, Purcell RH, Uchida,

eds. Viral Hepatitis C, D, and E. Amsterdam: Excerpta

Medica; 1991:205-209.

93. Hoofnagle JH, Lau D, Conjeervaram H, et al.

Prolonged therapy of chronic hepatitis C with

ribavirin. J Viral Hepatitis 1996;3:247-252.

94. Arase Y, Ikeda K, Murashima N. The long term

efficacy of glycyrrhizin in chronic hepatitis C

patients. Cancer 1997;79:1494-1500.

95. Xianshi S, Huiming C, Lizhuang W, et al. Clinical

and laboratory observation on the effect of

glycyrrhizin in acute and chronic viral hepatitis. J

Tradit Chin Med 1984;4:127-132.

96. Perissoud D, Weibel I. Protective effect of

(+)-cyanidanol-3 in acute liver injury induced by

galactosamine or carbon tetrachloride in the rat.

Naunyn Schmiedeberg's Arch Pharmacol 1980;312:285-291.

97. Balant L. Clinical pharmacology of

(+)-cyanidanol-3: a synopsis with emphasis on

pharmacokinetics. In: Conn HO, ed. International

Workshop on (+)-Cyanidanol-3 in Liver Diseases.

London: The Royal Society of Medicine; 1981:49-54.

98. Colman C, MY, Scheur PJ, et al. Treatment

of alcohol-related liver disease with

(+)-cyanidanol-3: a randomised double-blind trial. Gut

198;21:965-969.

99. World MJ, Aps EJ, Shaw GK, Thomson AD.

(+)-Cyanidanol-3 for alcoholic liver disease: results

of a six-month clinical trial. Alcohol Alcohol

1984;19:23-29.

100. Piazza M, Guadagnino V, Picciotto G, et al.

Effect of (+)-cyanidanol-3 in acute HAV, HBV, and

non-A, non-B viral hepatitis. Hepatology 1983;3:45-49.

101. Blum AL, Doelle W, Kortum K, et al. Treatment of

acute viral hepatitis with (+)-cyanidanol-3. Lancet

1977;2:1153-1155.

102. Di Nola F. (+)-Cyanidanol-3 in acute viral

hepatitis. Lancet 1980;2:1379-1380.

103. Piazza M, de Mercator R, Guadagnino V, et al.

Effect of (+)-cyanidnaol-3 on chronic persistent or

chronic active hepatitis. In: Conn HO, ed.

International Workshop on (+)-Cyanidanol 3 in Diseases

of the Liver. London: The Royal Society of Medicine;

1981:123-129.

104. Loginov AS, Dzhalalov KD, Blok IuE, et al.

Treatment of chronic diseases of the liver with

catergen. Ter Arkh 1986;58:73-76. [Article in Russian]

105. Suzuki H, Yamamato S, Hirayama C. Cianidanol

therapy for Hbe-antigen-positive chronic hepatitis: a

multicentre, double-blind study. Liver 1986;6:35-44.

106. Salama A, Mueller-Eckhardt C. Cianidanol and its

metabolites bind tightly to red cells and are

responsible for the production of auto- and/or

drug-dependent antibodies against these cells. Br J

Haematol 1987;66:263-266.

107. Gandolfo GM. Hemolytic anemia and

thrombocytopenia induced by cyanidanol. Acta Haematol

1992;88:96-99.

108. Luper S. A review of plants used in the treatment

of liver disease: Part 1. Altern Med Rev

1998;3:410-421.

109. Gagliardi B, Fiori GP. Results of a double blind

study on the effect of silymarin in the treatment of

acute viral hepatitis, carried out at two medical

centers. Med Klin 1978;73:1060-1065.

110. Moscarelli S, Guisti A, Marra F, et al.

Therapeutic and anti-lipoperoxidant effects of

silybin-phosphatidylcholine complex in chronic liver

disease: preliminary results. Curr Ther Res

1993;53:98-102.

111. Vailaii A, Arista I, Sozze E, et al. Randomized

open study of the dose-effect relationship of a short

course of IdB1016 in patients with viral or alcoholic

hepatitis. Fitoterapia 1993;64:219-228.

112. Mehrotra R, Rawat S, Kulshreshtha DK, et al. In

vitro studies on the effect of certain natural

products against hepatitis B virus. Indian J Med Res

1990;92:133-138.

113. Jayaram S, Thyagarajan SP. Inhibition of HBsAg

secretion from cell line by Phyllanthus

amarus. Indian J Pathol Microbiol 1996;39:211-215.

114. Ott M, Thyagarajan SP, Gupta S. Phyllanthus

amarus suppresses hepatitis B virus by interrupting

interactions between HBV enhancer I and cellular

transcription factors. Eur J Clin Invest

1997;27:908-915.

115. Wang M, Cheng H, Li Y, et al. Herbs of the genus

Phyllanthus in the treatment of chronic hepatitis B:

observations with three preparations from different

geographic sites. J Lab Clin Med 1995;126:350-352.

116. Thamlikitkul V, Wasuwat S, Kanchanapee P.

Efficacy of Phyllanthus amarus for eradication of

hepatitis B virus in chronic carriers. J Med Assoc

Thai 1991;74:381-385.

117. Milne A, Hopkirk N, Lucas CR, et al. Failure of

New Zealand hepatitis B carriers to respond to

Phyllanthus amarus. N Z Med J 1994;107:243.

118. Kann M, Gerlich W. Structure and molecular

virology. In: Zuckerman AJ, HC, eds. Viral

Hepatitis. London: Churchill Livingston;1998:77-99.

119. HC, Thurz MR. Pathogenesis of chronic

hepatitis B. In: Zuckerman AJ, HC, eds. Viral

Hepatitis. London: Churchill Livingston;1998.

120. Main J, HC. Treatment of chronic hepatitis

B. In: Zuckerman AJ, HC, eds. Viral Hepatitis.

London: Churchill Livingston;1998.

__________________________________________________